



# FRONTIERS IN HEPATOLOGY



## Non-alcoholic Fatty Liver Disease & the Metabolic Syndrome – Key questions on disease consequences and treatment –

24<sup>th</sup> November 2015

Venue: The Academy of Medical Sciences, 41 Portland Place, London, W1B 1QH

Scientific organisers: Professor Roger Williams CBE, Director, Institute of Hepatology, London and Professor Chris Day, Pro-Vice Chancellor and Professor of Liver Medicine, Newcastle University

-----0000000-----

08.30 – 08.55 *Registration and refreshments*

08.55 – 09.00 **Welcome and Introductory remarks**

Professor Roger Williams, CBE, Director, Institute of Hepatology, London, UK

### **INTERRELATIONSHIPS OF NAFLD AND METABOLIC SYNDROME**

**Chair: Professor Roger Williams, CBE, Institute of Hepatology, London**

09.00 – 09.25 **NAFLD 2015: An overview**

Professor Chris Day, Newcastle University, Newcastle, UK

09.25 – 09.50 **Metabolic Syndrome 2015: An overview**

Professor Michael Roden, UKD Heinrich Heine University, Düsseldorf, Germany

09.50 – 10.15 **NAFLD, insulin resistance and Metabolic Syndrome: chicken or egg?**

Professor Hannele Yki-Järvinen, University of Helsinki, Helsinki, Finland

10.15 – 10.40 **NAFLD in absence of Metabolic Syndrome**

Dr Yusuf Yilmaz, Marmara University, Istanbul, Turkey

10.40 – 11.10 *Refreshments*

### **FACTORS IN DISEASE PROGRESSION**

**Chair: Professor Chris Day, Newcastle University, Newcastle**

11.10 – 11.35 **Putative mechanisms and molecular pathways**

Dr Wing-Kin Syn, Institute of Hepatology, London, UK

11.35 – 12.00 **New links between liver and metabolism – bile acids, their receptors and FGFs**

Professor Michael Trauner, Medical University of Vienna, Vienna, Austria

12.00 – 12:25 **Influence of genetic factors**

Dr Quentin Anstee, Newcastle University, Newcastle, UK

12.25 – 12.50 **Natural history and predictors of disease progression**

Dr Mattias Ekstedt, Linköping University, Linköping, Sweden

12.50 – 13.15 **General discussion – Chair: Professor Chris Day, Newcastle University, Newcastle**

13.15 – 14.15 *Lunch*

**NEW, ESTABLISHED AND EMERGING THERAPIES**

**Chair: Professor Philip Newsome, University of Birmingham, Birmingham, UK**

14.15 – 14:40 **The role of modifying dietary factors and dietary supplements in the management of NAFLD**

Professor Christopher Byrne, University of Southampton, Southampton, UK

14.40 – 15.05 **Lifestyle strategies for NAFLD**

Professor Michael Trenell, Newcastle University, Newcastle, UK

15.05 – 15.30 **Emerging pharmacotherapies for NAFLD**

Professor Vlad Ratziu, Institute for Cardiometabolism and Nutrition, Paris, France

15.30 – 15.55 **Benefits of bariatric surgery including diabetes control**

Mr Andrew Jenkinson, University College London Hospital, London, UK

15.55 – 16.25 *Refreshments*

**APPROPRIATE HOSPITAL AND COMMUNITY CARE**

**Chair: Professor Simon Taylor-Robinson, Imperial College London, London, UK**

16.25 – 16.50 **The Metabolic Physician and multidisciplinary hospital care**

Professor Nick Finer, University College London Hospitals, London, UK

16.50 – 17.15 **Screening for NAFLD and NASH in the community**

Dr Stephen Ryder, University of Nottingham, Nottingham, UK

17.15 – 17.30 **EPoS and The European NAFLD Registry - a platform for collaborative research in NAFLD**

Dr Quentin Anstee, Newcastle University, Newcastle, UK

17.30 – 17.45 **Future directions – Chair: Professor Roger Williams, CBE, Institute of Hepatology, London and Professor Chris Day, Newcastle University, Newcastle**

**CPD accreditation by the Federation of the Royal Colleges of Physicians of the United Kingdom has been applied for**

-----0000000-----

**For details and to reserve a place at this meeting, please contact Enda O'Sullivan on 020-7255 9833 or e-mail: [e.o'sullivan@researchinliver.org.uk](mailto:e.o'sullivan@researchinliver.org.uk)**



**EPoS: Elucidating Pathways of Steatohepatitis**  
Funded by the Horizon 2020 Framework Program of the European Union under Grant Agreement 634413.



*This meeting is also sponsored with an unconditional educational grant from the following pharmaceutical company:-*

Principal sponsor



Norgine is a successful, independent European specialty pharmaceutical company that has been established for over 100 years and has a presence in all major European markets, focusing upon gastroenterology, hepatology, critical and supportive care.

For more information: [www.norgine.com](http://www.norgine.com) or phone 01895 826600

UK/COR/0214/0017  
Date of Prep February 2014